Publications by authors named "Daniel Leal-Alviarez"
Article Synopsis
- The study focuses on the need for faster treatment of immune checkpoint inhibitor-related pneumonitis (ICI-P), which is a serious condition in lung cancer patients.
- The implementation of a clinical care pathway algorithm aimed to shorten the time from diagnosis to treatment, showing a significant increase in the use of immunotoxicity order sets.
- While the direct time to treatment didn't significantly change, improvements in follow-up care and patient management were noted, emphasizing the importance of standardized practices in treating this condition.
Purpose: Immune checkpoint inhibitor-related pneumonitis (ICI-P) is a condition associated with high mortality, necessitating prompt recognition and treatment initiation. This study aimed to assess the impact of implementing a clinical care pathway algorithm on reducing the time to treatment for ICI-P.
Methods: Patients with lung cancer and suspected ICI-P were enrolled, and a multi-modal intervention promoting algorithm use was implemented in two phases.
The high incidence of resistance to Tyrosine Kinase Inhibitors (TKIs) targeted against EGFR and downstream pathways has increased the necessity to identify agents that may be combined with these therapies to provide a sustained response for breast cancer patients. Here, we investigate the therapeutic potential of Ganoderma lucidum extract (GLE) in breast cancer, focusing on the regulation of the EGFR signaling cascade when treated with the EGFR TKI, Erlotinib. SUM-149, or intrinsic Erlotinib resistant MDA-MB-231 cells, and a successfully developed Erlotinib resistant cell line, rSUM-149 were treated with increasing concentrations of Erlotinib, GLE, or their combination (Erlotinib/GLE) for 72h.
View Article and Find Full Text PDF